Brief: Qsam Biosciences Says Co Granted Telix An Additional 30 Days Under Exclusivity Period To Complete Its Due Diligence
16/01/2024 23:05
Jan 16 (Reuters) - Qsam Biosciences Inc QSAM.PK :
* QSAM BIOSCIENCES: ON JAN 11, 2024, CO GRANTED TELIX AN
ADDITIONAL 30 DAYS UNTIL FEB 14, 2024 UNDER EXCLUSIVITY PERIOD
TO COMPLETE ITS DUE DILIGENCE
Further company coverage: QSAM.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Qsam Biosciences
See all newsBrief: QSAM Biosciences Signs Definitive Agreement To Be Acquired By Telix Pharmaceuticals
Brief: Qsam Biosciences Says Co Granted Telix An Additional 30 Days Under Exclusivity Period To Complete Its Due Diligence
Brief: Qsam Biosciences Signs Term Sheet To Be Acquired By Telix Pharmaceuticals Receives $2 Million Pre-Closing Collaboration And Option Fee
Brief: Telix Pharmaceuticals Announces Proposed Acquisition Of QSAM Biosciences
Brief: Qsam Biosciences Provides Update To Shareholders On Phase 1 Progress And Preliminary Clinical Data